Comparative Changes of Lipid Levels in Treatment-Naive HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz Raltegravir and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks

摘要

Background and ObjectivesLong-term use of antiretroviral therapy (ART) to treat HIV infection has been associated with dyslipidemia and metabolic and cardiovascular complications. Available options for patients at risk of cardiovascular disease include antiretroviral drugs with improved lipid profiles. Dolutegravir is one of a new generation of HIV integrase inhibitors recently incorporated into the US Department of Health and Human Services, German, Spanish, and Italian HIV treatment guidelines as a preferred first-line third agent in combination with dual nucleoside reverse transcriptase inhibitor (NRTI) backbone therapies. To understand the lipid profile of dolutegravir in the context of combination ART, we analyzed the lipid outcomes at 48 weeks in ART-naive participants in four phase IIb–IIIb clinical trials.